NEUMORA THERAPEUTICS, INC.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $-366.0M | — |
| Jun 2022 | — | $-394.7M | — |
| Sep 2022 | — | $-422.0M | $252.5M |
| Dec 2022 | — | $-446.9M | $240.9M |
| Mar 2023 | — | $-477.9M | $210.9M |
| Jun 2023 | — | $-513.5M | $204.2M |
| Sep 2023 | — | $512.7M | $412.3M |
| Dec 2023 | — | $469.1M | $374.0M |
| Mar 2024 | — | $424.5M | $182.9M |
| Jun 2024 | — | $381.3M | $150.7M |
| Sep 2024 | — | $320.7M | $275.7M |
| Dec 2024 | $0 | $287.1M | $142.1M |
| Mar 2025 | — | $228.4M | $126.9M |
| Jun 2025 | $19.5M | $182.9M | $124.5M |
| Sep 2025 | $19.6M | $132.2M | $129.1M |
| Dec 2025 | $54.5M | $103.9M | $182.5M |
| Mar 2026 | $53.0M | $70.7M | $147.1M |
| Jun 2026 | $52.9M | $44.5M | $116.8M |